BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22917549)

  • 1. Arginine deprivation as a new treatment strategy for head and neck cancer.
    Huang CC; Tsai ST; Kuo CC; Chang JS; Jin YT; Chang JY; Hsiao JR
    Oral Oncol; 2012 Dec; 48(12):1227-35. PubMed ID: 22917549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
    Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
    Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
    Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
    Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
    Kim JH; Kim JH; Yu YS; Kim DH; Min BH; Kim KW
    Oncol Rep; 2007 Dec; 18(6):1373-7. PubMed ID: 17982619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
    Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
    Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
    Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
    Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine deprivation as a targeted therapy for cancer.
    Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
    Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
    Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
    Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
    Walts AE; Bomalaski JS; Ines D; Orsulic S
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1363-9. PubMed ID: 25548129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
    Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
    Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
    Stelter L; Evans MJ; Jungbluth AA; Longo VA; Zanzonico P; Ritter G; Bomalaski JS; Old L; Larson SM
    Mol Imaging; 2013; 12(1):67-73. PubMed ID: 23348793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
    Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
    Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes.
    Bobak YP; Vynnytska BO; Kurlishchuk YV; Sibirny AA; Stasyk OV
    Cell Biol Int; 2010 Nov; 34(11):1085-9. PubMed ID: 20653567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
    Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
    Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma.
    Wu L; Li L; Meng S; Qi R; Mao Z; Lin M
    J Gastroenterol Hepatol; 2013 Feb; 28(2):365-8. PubMed ID: 23339388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
    Savaraj N; Wu C; Kuo MT; You M; Wangpaichitr M; Robles C; Spector S; Feun L
    Drug Target Insights; 2007; 2():119-28. PubMed ID: 21901069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
    Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
    Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.